首页EVGN • NASDAQ
add
Evogene Ltd
相关资讯
财务信息
损益表
收入
净收入
| (USD) | 2025年9月info | 年同比变化 |
|---|---|---|
收入 | 31.20万 | -82.63% |
经营支出 | 287.90万 | -64.76% |
净收入 | 387.40万 | 150.77% |
净利润率 | 1241.67 | 392.27% |
每股收益 | -0.46 | 64.51% |
息税折旧摊销前利润 | -244.30万 | 64.22% |
有效税率 | -0.04% | — |
资产负债表
总资产
负债总额
| (USD) | 2025年9月info | 年同比变化 |
|---|---|---|
现金及短期投资 | 1595.80万 | -20.02% |
总资产 | 2608.60万 | -34.97% |
负债总额 | 883.40万 | -68.31% |
权益总额 | 1725.20万 | — |
发行在外的股份 | 871.64万 | — |
市净率 | 6.45 | — |
资产回报率 | -22.70% | — |
资本回报率 | -39.13% | — |
现金流
现金净变动
| (USD) | 2025年9月info | 年同比变化 |
|---|---|---|
净收入 | 387.40万 | 150.77% |
来自运营的现金 | -333.30万 | 32.37% |
投资现金 | 1090.90万 | 441.12% |
融资现金 | -1033.60万 | -318.34% |
现金净变动 | -270.30万 | -247.46% |
自由现金流 | -38.56万 | -131.18% |
简介
Evogene is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs.
In 2024, the company began collaborating with Google Cloud to develop an AI-powered generative model aimed at discovering small molecules for drug development and sustainable agriculture. Wikipedia
CEO
成立时间
1999
员工数量
117